[BREAKING] Hemerion obtains the FDA clearance for its next US clinical trial


Deeptech Connect 2023

Hemerion one of 100 start-ups at Deeptech Connect

Hemerion is taking part for the first time in Deeptech Connect, an event organized by the SATTs (Tech Transfer Acceleration Companies), which brings together 100 start-ups created from disruptive technologies developed by French academic research.

Created as part of the French “Investing in the Future” program,  the SATTs ( Tech Transfer Acceleration Companies) finance the technological development of innovations stemming from French public research. In particular, they play an essential role in the valorization of research work within innovative companies.

The network of France’s 13 SATTs is organizing the second edition of Deeptech Connect, a day dedicated to disruptive technologies, on November 14, 2023 at the Carreau du Temple in Paris.

Hemerion has been invited to take part in this event in the Health category. The technology developed by Hemerion is the result of joint research by INSERM, the Lille University Hospital and the University of Lille. The technology has been licensed internationally by the SATT Nord (Northern France).

Deeptech Connect is the first event to bring together industrialists and investors with start-ups from French academic research. This year, it will bring together 100 start-ups created around disruptive technologies.

Deeptech will also host a number of conferences led by leading experts who will offer a forward-looking look at the French and international innovation ecosystems, the synergies between public research and industrial issues, and the key elements of entrepreneurial success in the Deeptech world.